First In Human Study of CX-2051 in Advanced Solid Tumors
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
| Condition(s) | Solid Tumor, Adult |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors. |
| Who can participate | Inclusion Criteria: * Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Measurable disease per RECIST v1.1 * Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue * Additional inclusion criteria may apply Exclusion Criteria: * Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated * Known active central nervous system (CNS) involvement by malignancy * Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1 * Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload * Major surgery (requirin |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | CytomX Therapeutics |
| Locations | Denver, Colorado, United States; Boston, Massachusetts, United States; The Bronx, New York, United States; Huntersville, North Carolina, United States; Nashville, Tennessee, United States; San Antonio, Texas, United States (+1 more sites) |
| Start date | 2024-04-02 |
| NCT ID | NCT06265688 |
| Official listing | https://clinicaltrials.gov/study/NCT06265688 |